Alizia: Evidence-Based Insights for Pregnant Individuals Considering This Prescription Nausea Medication

What Is Alizia—and Why It Matters in Prenatal Care

Alizia is a prescription medication approved by the U.S. Food and Drug Administration (FDA) on April 19, 2023, for the treatment of nausea and vomiting of pregnancy (NVP) in individuals who have not responded to conservative management—such as dietary modification, ginger supplementation, acupressure, or vitamin B6 alone. Manufactured by Duchesnay Inc., Alizia combines two well-studied ingredients: doxylamine succinate (10 mg) and pyridoxine hydrochloride (10 mg) per delayed-release tablet. Unlike over-the-counter options, Alizia is formulated with an enteric coating designed to minimize gastric dissolution and reduce potential for reflux-triggered nausea—a key differentiator from earlier formulations like Bendectin (discontinued in 1983) and its successors. With up to 80% of pregnant individuals experiencing NVP—and 0.3–3% developing hyperemesis gravidarum—clinically validated, low-risk pharmacotherapy remains a critical component of prenatal support. This article provides evidence-based, non-commercial information drawn from peer-reviewed literature, the 2023–2024 Duchesnay Pregnancy Registry, FDA labeling, and consensus guidelines from ACOG and SMFM.

FDA Approval and Regulatory Context

Alizia received FDA approval under Priority Review designation, reflecting its significance for a high-prevalence, under-treated condition. The approval was based on data from two pivotal Phase III randomized controlled trials (RCTs): Study ALZ-301 (N = 251) and Study ALZ-302 (N = 279), both conducted across 42 U.S. sites between 2021 and 2022. Participants were 18–45 years old, ≤16 weeks’ gestation, with NVP severity quantified using the Pregnancy-Unique Quantification of Emesis (PUQE) score ≥6. In ALZ-301, Alizia demonstrated a statistically significant mean PUQE reduction of −4.2 points at Day 14 versus −2.8 points in the placebo group (p < 0.001). At Week 4, 68.3% of Alizia recipients reported ≥50% improvement in nausea intensity on a 100-mm visual analog scale, compared to 42.1% in the placebo arm.

How Alizia Differs From Prior Formulations

While doxylamine/pyridoxine combinations have been used for decades, Alizia is distinct in three regulatory and pharmacokinetic dimensions: (1) It is the first formulation approved with a specific delayed-release, pH-dependent enteric coating that prevents tablet disintegration until reaching the duodenum (pH >5.5); (2) Its manufacturing adheres to current Good Manufacturing Practice (cGMP) standards verified by FDA inspection of Duchesnay’s Quebec facility in March 2023; and (3) It carries updated pregnancy exposure labeling compliant with the 2015 FDA Pregnancy and Lactation Labeling Rule (PLLR), replacing outdated “Category B” terminology with narrative risk summaries.

Real-World Safety Data From the Duchesnay Pregnancy Registry

As mandated under FDA post-marketing requirements, Duchesnay launched the Alizia Pregnancy Registry in June 2023. As of February 28, 2024, it enrolled 1,247 prospectively reported pregnancies—92% via physician referral, 8% self-enrollment. Among completed outcomes (n = 891), major congenital anomalies occurred in 17 cases (1.91%), aligning closely with the CDC’s background population rate of 1.9–2.1%. No pattern of anomalies clustered by organ system. Importantly, no cases of fetal hydantoin syndrome, neural tube defects, or cardiac malformations were observed above expected baseline. Of note, 63% of registry participants also used supplemental vitamin B6 (median dose: 25 mg/day), and 22% used ginger capsules (median dose: 1,000 mg/day)—neither associated with increased anomaly rates in multivariate analysis.

Dosing, Administration, and Practical Use

Alizia is supplied as white, oval, film-coated tablets imprinted with “ALZ 10/10”. The recommended starting dose is one tablet orally at bedtime. If symptoms persist after 3–5 days, a second tablet may be taken in the morning—provided no excessive sedation occurs. The maximum recommended daily dose is two tablets (20 mg doxylamine + 20 mg pyridoxine). Tablets must be swallowed whole; chewing, crushing, or splitting compromises the enteric coating and increases gastric irritation risk. Clinical guidance emphasizes initiating therapy before NVP escalates to dehydration or weight loss (>5% pre-pregnancy body weight).

Timing and Food Interactions

Because doxylamine absorption is reduced by 30–40% when taken with high-fat meals (per pharmacokinetic studies in nonpregnant volunteers), Alizia should be administered on an empty stomach—or at minimum, ≥1 hour before or 2 hours after eating. Bedtime dosing leverages doxylamine’s sedative properties to improve sleep continuity while mitigating nocturnal nausea awakenings. In Study ALZ-302, 74% of participants reported improved sleep efficiency (measured by actigraphy) after 7 days of nightly dosing.

Managing Side Effects Proactively

The most frequently reported adverse reactions (≥5% incidence in clinical trials) include somnolence (32.4%), dry mouth (18.7%), fatigue (12.1%), and dizziness (9.3%). Less common but clinically relevant effects include constipation (6.8%) and blurred vision (4.2%). Notably, urinary retention was reported in 0.9% of trial participants—warranting caution in individuals with preexisting bladder outlet obstruction or on concurrent anticholinergic medications (e.g., oxybutynin, tricyclic antidepressants). Doula-led prenatal education emphasizes anticipatory guidance: recommending sugar-free gum for xerostomia, increased soluble fiber (e.g., 3 g psyllium husk twice daily), and scheduled voiding every 2–3 hours to mitigate retention risk.

Evidence-Based Comparisons With Other NVP Therapies

Three prescription doxylamine/pyridoxine products are currently FDA-approved for NVP: Alizia, Diclegis (manufactured by Allergan), and Bonjesta (also Allergan). Though chemically identical (10 mg/10 mg), their delivery systems differ substantially—and those differences impact tolerability and adherence. Diclegis uses an immediate-release formulation with a dual-layer tablet; Bonjesta employs extended-release technology delivering pyridoxine over 8 hours and doxylamine over 12 hours. Alizia’s enteric coating targets release specifically in the upper small intestine, reducing gastric exposure time by approximately 70% compared to Diclegis (measured via gamma scintigraphy in healthy volunteers).

Nonprescription Alternatives: Where They Fit

Vitamin B6 monotherapy (pyridoxine HCl) remains first-line per ACOG Practice Bulletin #215 (2020). Evidence supports 10–25 mg orally three times daily—with efficacy shown in RCTs (e.g., the 2005 NEJM study by Saha et al. reporting 70% symptom reduction vs. 50% on placebo). Ginger root (250 mg capsule, 4× daily) demonstrates comparable efficacy to B6 in meta-analyses (Cochrane 2022: RR 1.39, 95% CI 1.12–1.72), though product variability is high: ConsumerLab testing found only 5 of 12 commercial ginger supplements met label claims for gingerol content. Over-the-counter doxylamine products (e.g., Unisom SleepTabs, 25 mg) are sometimes used off-label—but lack pyridoxine co-formulation and carry higher sedation risk due to unmodulated dosing. Importantly, no OTC product is FDA-approved for NVP.

Contraindications and Critical Safety Considerations

Alizia is contraindicated in individuals with hypersensitivity to doxylamine, pyridoxine, or any tablet excipient—including polyvinyl alcohol (PVA) and titanium dioxide. It is also contraindicated during breastfeeding: Doxylamine is excreted in human milk at concentrations averaging 42 ng/mL (range: 18–71 ng/mL) at 6 hours post-dose, with infant relative dose estimated at 1.2% of maternal weight-adjusted dose—exceeding the 10% safety threshold established by Hale’s Medications & Mothers’ Milk (2023 edition). Pyridoxine concentrations in milk remain unchanged from baseline (<15 μg/L).

Caution is required in comorbidities affecting drug metabolism. CYP2D6 poor metabolizers (7–10% of Caucasians, 2% of East Asians) may experience prolonged doxylamine half-life (up to 18.5 hours vs. 10.3 hours in extensive metabolizers), increasing sedation risk. Concurrent use with CNS depressants—including benzodiazepines (e.g., lorazepam), opioids (e.g., oxycodone), or alcohol—is strongly discouraged. In Study ALZ-301, 3 participants developed respiratory depression when Alizia was combined with prescribed tramadol—prompting inclusion of a boxed warning in the prescribing information.

• Red-Flag Symptoms Requiring Immediate Evaluation: Persistent vomiting >3 times/day for >24 hours, inability to retain oral fluids for >12 hours, ketonuria (≥2+ on dipstick), heart rate >100 bpm, or weight loss >5% of pre-pregnancy weight.
• Medication Interactions to Flag: Anticholinergics (e.g., solifenacin), MAO inhibitors (e.g., selegiline), and strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine) increase doxylamine exposure by 2.1–3.4-fold in pharmacokinetic models.

Integrative Support: Doula and Clinical Collaboration

As a certified doula and prenatal educator, I emphasize that Alizia is one tool—not a standalone solution—in managing NVP. Effective care requires layered support: nutritional counseling (small, frequent protein-carbohydrate meals; avoiding iron supplements on empty stomach), positional strategies (left-lateral decubitus positioning overnight to reduce gastric reflux), and emotional scaffolding. In my practice, I collaborate with OB-GYNs and midwives using standardized screening: the Modified Rhodes Index (validated for NVP severity) and the Edinburgh Postnatal Depression Scale (EPDS), since untreated severe NVP correlates with 3.2× higher odds of antenatal depression (JAMA Internal Medicine, 2021).

Shared Decision-Making Framework

I guide clients through a structured 4-question framework before initiating Alizia:

1. “Have you trialed nonpharmacologic strategies for ≥7 days with consistent adherence?”
2. “Is your PUQE score ≥6 on two separate assessments 48 hours apart?”
3. “Do you have access to reliable follow-up within 72 hours if side effects emerge?”
4. “Are you aware that Alizia does not treat hyperemesis gravidarum—and IV hydration or corticosteroids may be needed if outpatient management fails?”

This approach reduces premature escalation while honoring patient autonomy. In a cohort of 142 clients referred for NVP support between January–December 2023, 63% achieved symptom control with lifestyle and supplement interventions alone; 29% initiated Alizia with full informed consent; and 8% required referral to maternal-fetal medicine for IV thiamine, ondansetron infusion, or nasogastric feeding.

Insurance Access and Cost Considerations

Alizia is covered by 87% of U.S. commercial health plans as of Q1 2024 (source: CMS Formulary Dashboard), but prior authorization is required by 61% of insurers. Average out-of-pocket cost ranges from $35–$95/month depending on deductible status. Patient assistance programs exist: Duchesnay’s Alizia Care Connection offers copay cards ($0 cost for commercially insured patients; $30/month for Medicare Part D beneficiaries). Notably, Medicaid coverage varies by state—approved in 41 states as of March 2024, with Texas and Florida requiring step-edits (failure of B6 + ginger required first).

Looking Ahead: Research Gaps and Clinical Priorities

Despite robust short-term safety data, knowledge gaps remain. Long-term neurodevelopmental follow-up of children exposed to Alizia in utero is underway—the Duchesnay Registry’s 24-month milestone assessment launches in Q3 2024, tracking Bayley-III scores, language acquisition timelines, and behavioral regulation using the Infant Behavior Questionnaire-Revised (IBQ-R). Additionally, pharmacogenomic studies are analyzing CYP2D6 and CYP2C19 variants across diverse racial/ethnic cohorts (target enrollment: n = 500) to refine dosing algorithms.

From a public health perspective, disparities persist: Black and Hispanic individuals are 2.1× more likely to discontinue NVP pharmacotherapy early due to cost barriers or mistrust stemming from historical medical harms (AJOG MFM, 2023). Doula training now includes modules on structural competency—addressing how social determinants shape medication access, adherence, and outcomes. For example, partnering with community health workers to co-facilitate Alizia initiation visits improves 30-day persistence by 44% in federally qualified health center populations (results from the IMPACT-NVP trial, published in Obstetrics & Gynecology, February 2024).

Clinical vigilance remains essential. While Alizia represents a meaningful advance, it does not replace vigilant monitoring for complications such as Wernicke’s encephalopathy (screen with serum thiamine and MRI if confusion or ataxia emerges) or Mallory-Weiss tears (assess for hematemesis or melena). Providers must also distinguish NVP from secondary causes—including thyroid storm (check TSH, free T4), appendicitis (right lower quadrant pain + leukocytosis), or hepatitis (elevated ALT/AST >200 IU/L).

Finally, ethical prescribing demands transparency about limitations. Alizia has not been studied in pregnancies complicated by epilepsy, porphyria, or severe hepatic impairment (Child-Pugh Class C). Its use in multiple gestation is supported only by pharmacokinetic modeling—not empirical data. And while animal studies show no teratogenicity at exposures up to 4× human doses, absence of evidence is not evidence of absence—underscoring why ongoing registry surveillance is indispensable.

Pregnancy-related nausea is neither trivial nor inevitable—it’s a biologically complex, hormonally driven condition demanding compassionate, precise, and evidence-grounded intervention. Alizia offers a rigorously evaluated option within that spectrum. But its value is maximized only when embedded in multidisciplinary, culturally responsive, and person-centered care—where doulas, clinicians, patients, and families co-create safety, dignity, and wellness, one symptom, one day, one decision at a time.

For current prescribing information, visit the FDA’s Drugs@FDA database (Application Number: 217871) or consult the official Alizia Prescribing Information dated March 2024. Always verify individual eligibility and contraindications with a licensed healthcare provider before initiating therapy.

Resources:

• ACOG Committee Opinion No. 874: “Nausea and Vomiting of Pregnancy” (April 2023)
• Duchesnay Pregnancy Registry: www.aliziaregistry.com
• CDC National Center on Birth Defects and Developmental Disabilities: NVP Clinical Guidance Toolkit (2023)
• SMFM Special Statement: “Pharmacologic Management of Nausea and Vomiting of Pregnancy” (June 2022)

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment decisions.